好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | H217 - Clinical Trials Diversity: A Surmountable Problem (Research Hub)

Wednesday 04/17/24
01:00 PM - 01:30 PM MDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Hubs (Research)
Richard T. Benson, MD, PhD, FAAN, Yazmin Odia, MD, MS, FAAN, FAAN, Shibani S. Mukerji, MD, PhD
General Neurology, 好色先生, Research, and Methodology
The lack of diversity in clinical trials is a problem. Join us to discuss why and how diversity is integral to clinical trial conduct and impact.
No CME available
Patient Care & Procedural Skills, Practice-based Learning and Improvement, Systems-based Practice
Introductory
Diversity, Equity, and Inclusion
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student
Didactic, Audience Participation

Program Evaluations

Event Timeline
01:00 PM - 01:30 PM MDT Speaker Clinical Trials Diversity: A Surmountable Problem
Richard T. Benson, MD, PhD, FAAN, Yazmin Odia, MD, MS, FAAN, FAAN, Shibani S. Mukerji, MD, PhD, Claire Riley, MD, FAAN
Faculty Disclosures
Richard T. Benson, MD, PhD, FAAN Dr. Benson has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Journals (AAN). Dr. Benson has received personal compensation in the range of $100,000-$499,999 for serving as a Federal employee with HHS/NIH.
Yazmin Odia, MD, MS, FAAN, FAAN Dr. Odia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile.
Shibani S. Mukerji, MD, PhD Dr. Mukerji has stock in Gilead Science. Dr. Mukerji has stock in Ranpack. Dr. Mukerji has stock in Snowflake. An immediate family member of Dr. Mukerji has stock in Amgen. The institution of Dr. Mukerji has received research support from NIH. The institution of Dr. Mukerji has received research support from Massachusetts General Hospital.
Claire Riley, MD, FAAN Dr. Riley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cabaletta Bio. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb.